Endocrine Cancer

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Insulin Products

Insulin products table with pharmacokinetic properties.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules

Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules

By

Molecular testing may identify benign disease in some patients with thyroid nodules classified as suspicious for malignancy, helping them avoid unnecessary treatment.

Lobectomy Rates for Low-Risk DTC Are Rising

Lobectomy Rates for Low-Risk DTC Are Rising

By

Adherence to the 2015 recommendation from ATA — to use lobectomy rather than complete thyroidectomy for low-risk differentiated thyroid cancer — is increasing.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Malignancy Rates Higher in Children With Indeterminate Thyroid Nodules

Malignancy Rates Higher in Children With Indeterminate Thyroid Nodules

By

Malignancy was more common in children with thyroid nodules classified as indeterminate by BSRTC criteria compared with adults.

RET Inhibitor May Be Effective in <I>RET</I>-Altered Thyroid Cancers

RET Inhibitor May Be Effective in RET-Altered Thyroid Cancers

By

RET inhibitor LOXO-292 was well tolerated and demonstrated high antitumor activity against RET-altered thyroid cancers.

Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival

Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival

By

Childhood radiation-induced thyroid cancer does not affect all-cause mortality compared with healthy individuals.

MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer

MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer

By

The addition of selumetinib to radioactive iodine did not improve the complete remission rate among patients with high-risk nonmetastatic differentiated thyroid cancer.

Investigators Pinpoint Immune-Related Genes That Are Upregulated in ATC and PTC

Investigators Pinpoint Immune-Related Genes That Are Upregulated in ATC and PTC

By

Immune-related gene sets, including those for PD-L1/L2, are upregulated in ATC and PTC, but not in poorly differentiated disease or normal tissue.

US Centers Fail to Analyze Neck Lymph Nodes in Preoperative Ultrasounds for Thyroid Cancer

US Centers Fail to Analyze Neck Lymph Nodes in Preoperative Ultrasounds for Thyroid Cancer

By

Most imaging centers in the United States fail to analyze lateral neck lymph nodes during preoperative ultrasounds in patients with thyroid cancer.

PRRA Fails to Improve Long-Term Outcomes in Low-Risk Papillary Thyroid Cancer

PRRA Fails to Improve Long-Term Outcomes in Low-Risk Papillary Thyroid Cancer

By

Postoperative radioiodine remnant ablation did not improve long-term outcomes among patients with low-risk papillary thyroid carcinoma.

Recombinant Human Thyrotropin Use Has No Effect on Outcomes After Radioiodine in DTC

Recombinant Human Thyrotropin Use Has No Effect on Outcomes After Radioiodine in DTC

By

Outcomes after radioiodine therapy are similar after preparation with either recombinant human thyrotropin or thyroid hormone withdrawal.

Ethanol Sensitization May Improve RFA of Benign Thyroid Nodules

Ethanol Sensitization May Improve RFA of Benign Thyroid Nodules

By

Ethanol sensitization before radiofrequency ablation of benign thyroid nodules reduced time, ablation energy, and complications compared with conventional ablation.

Soluble PD-L1 Levels Associated With Disease-Free Survival in Papillary Thyroid Cancer

Soluble PD-L1 Levels Associated With Disease-Free Survival in Papillary Thyroid Cancer

By

High serum soluble PD-L1 levels are associated with shorter disease-free survival among patients with papillary thyroid cancer.

BABA Robotic Thyroidectomy Determined to Be Safe and Effective

BABA Robotic Thyroidectomy Determined to Be Safe and Effective

By

The BABA robotic thyroidectomy technique appears to be safe, with excellent outcomes in benign and malignant thyroid disease.

Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer

Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer

By

Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.

Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer

Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer

By

The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.

Thyroid irAEs Common With PD-L1 Inhibitors

Thyroid irAEs Common With PD-L1 Inhibitors

By

Thyroid-based immune-related adverse events are common among patients treated with PD-L1 inhibitors.

First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid Cancer

First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid Cancer

By

Pembrolizumab plus chemoradiotherapy failed to improve survival and lead to unexpected deaths in a small study of patients with anaplastic thyroid cancer.

TRK Inhibitor Effective in TRK-Fusion Advanced Thyroid Cancer

TRK Inhibitor Effective in TRK-Fusion Advanced Thyroid Cancer

By

The TRK inhibitor larotrectinib was effective and well tolerated among patients with relapsed/refractory advanced TRK-fusion thyroid cancer.

Several Driver Genes, Tumor Suppressors Found to Be Mutated in Anaplastic Thyroid Cancer

Several Driver Genes, Tumor Suppressors Found to Be Mutated in Anaplastic Thyroid Cancer

By

Tumor suppressor and driver genes are frequently mutated in Korean patients with anaplastic thyroid cancer.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer

Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer

By

Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.

<i>KRAS</i> Mutations May Influence Location, Local Recurrence of Resected Pancreatic Cancer

KRAS Mutations May Influence Location, Local Recurrence of Resected Pancreatic Cancer

By

Different KRAS mutations may be associated with differing primary tumor locations and patterns of local recurrence in resected pancreatic cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs